Steven Prestrelski, Chief Scientific Officer at XERIS PHARMACEUTICALS INC (XERS), sold 31,440 shares at $15.82 ($497K) on 2018-12-26, disclosed to the SEC on 2019-01-02.
Open-market sale of $497k XERS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.82 | 15,720 | $249K | 50.0% |
| 2 | $15.82 | 15,720 | $249K | 50.0% |
| Total | $15.82 avg | 31,440 | $497K | 100% |
| Filing → |
| XERS | SELL | 2021-01-15 | $60K | — | Filing → |
| XERS | SELL | 2021-01-12 | $57K | — | Filing → |
| XERS | SELL | 2020-01-14 | $55K | — | Filing → |